So far in 2021 there have been quite a few Initial Public Offerings (IPOs) available on the market. There are a number of major upcoming IPOs that you need to watch out for this week.
1. Frontier Group Holdings
Frontier Group Holdings ULCC is a holding company that provides air transportation services. Frontier Groups Holdings is poised to offer 30,000,000 shares of stock on the Nasdaq at a target price of $19-$21 on the week of March 29th. They filed to raise $600 million through an IPO of its common stock. The company strives to offer low cost air transportation for passengers in North America.
2. Flora Growth
Flora Growth FLGC is a cannabis company that produces naturally grown medicinal-grade cannabis oils and extracts in the world. They intend to offer 3,333,333 shares of stock at a target price of $14-$5 on the week of March 29th. They supply pharmaceutical and cosmetic companies with the highest-quality CBD oils and derivatives in the market.
3. Coursera
Coursera COUR is an online course provider that works with universities to provide educational content. They provide online courses, certifications, and degrees in a variety of subjects. Coursera intends to offer 15,730,000 shares at a target price between $30-$33 on the week of March 29th. Coursera was founded in 2012 and over 150 universities now use their platform.
See also: How to Buy Coursera IPO
4. Inspira Technologies OXY
Inspira Technologies OXY IINN is a medical firm that is working to develop respiratory support system technologies for hospitals. Inspira Technologies is poised to offer 2,750,000 shares of stock at a target price of $5.50 -$6.50 on the week of March 31st. They have filed to raise $16.5 million in an IPO with ordinary stocks.
5. Achilles Therapeutics
Achilles Therapeutics ACHL is a biopharmaceutical company that develops personalised T cell therapies targeting neoantigens to help with cancer. Achilles Therapeutics is poised to offer 9,750,000 shares of stock at a target price of $17-$19 on the Nasdaq. They focus on the development of the next generation of personalised immunotherapies to treat cancer.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.